Rakesh R. Ramjiawan
Harvard University(US)Massachusetts General Hospital(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Cancer, Hypoxia, and Metabolism, Cancer Mechanisms and Therapy, Hepatocellular Carcinoma Treatment and Prognosis, Angiogenesis and VEGF in Cancer
Most-Cited Works
- → Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?(2017)687 cited
- → CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice(2014)451 cited
- → Dual Programmed Death Receptor‐1 and Vascular Endothelial Growth Factor Receptor‐2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma(2019)400 cited
- → Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma(2020)145 cited
- → An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis(2015)117 cited
- → The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation(2017)110 cited
- → Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy(2020)83 cited
- → Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors(2017)81 cited
- → Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma(2021)76 cited
- → Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model(2021)26 cited